Leerink analyst Paul Matteis believes that the median seizure reduction demonstrated by Zogenix's (ZGNX) ZX008 compares favorably to the reduction in convulsive seizures seen in the placebo arm of the recent GW Pharmaceuticals (GWPH) Epidiolex phase 3 Dravet study, though he noted that Zogenix data represents a small sample and was generated at a single clinical site. Still, the new data continues to reflect ZX008's "encouraging efficacy across various types of motor seizures" and the drug's safety data also look favorable, Matteis tells investors. The firm keeps an Outperform rating on Zogenix shares.